Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

NCT03747133 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03747133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03747133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Recruiting
Start date
November 1, 2018
Completion date
November 30, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal tumor